Pharma services group Ergomed PLC (AIM:ERGO, ETR:2EM) said 2021 adjusted EBITDA will be ahead of market expectations with the growth of the US business the stand-out feature of the company’s performance.
Total revenue for the 12 months advanced by 37.2% to £118.6mln, with acquisitions augmenting organic expansion. Turnover in the States was up 59.5%.
Across all metrics, Ergomed’s performance was strong: the order book was £240mln, up 24.4%, while the firm’s cash position increased by £20mln to £32.2mln.
Looking ahead, the company said it was well-positioned in the “resilient and fast-growing” rare disease, oncology and pharmacovigilance sectors.
Chairman, Dr Miroslav Reljanović, added: "We start 2022 with an exceptionally strong platform - a robust order book, a track record of delivery and an offering that demonstrably meets the needs of a growing market.
“Ergomed is firmly positioned for further growth, both organically and through M&A, via geographic expansion and broadening of our service offering.
“We remain extremely confident in our future as a leading global provider of specialist pharmaceutical services."